INOZYME PHARMA, INC. Proceeds from Long-Term Debt Issued
INOZYME PHARMA, INC. reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-03-10
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for the quarter ending 2024-09-30 was $0.00.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for fiscal 2023 was $40.00M, a 887.65% increase from fiscal 2022.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for fiscal 2022 was $4.05M.
- INOZYME PHARMA, INC. proceeds from issuance of long-term debt for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $0.00 10-K · filed 2025-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | $12.50M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $12.50M derived: sum of 3 quarters · filed 2025-03-10 | $12.50M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $12.50M derived: sum of 2 quarters · filed 2025-03-10 | $12.50M derived: sum of 3 quarters · filed 2025-03-10 | $20.00M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $12.50M derived: sum of 2 quarters · filed 2025-03-10 | $20.00M derived: sum of 3 quarters · filed 2025-03-10 | $40.00M 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.50M derived: sum of 2 quarters · filed 2024-11-05 | $27.50M 10-Q · filed 2024-11-05 | $27.50M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $27.50M 10-Q · filed 2024-08-06 | $27.50M derived: sum of 3 quarters · filed 2024-08-06 | $31.55M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $20.00M 10-Q · filed 2024-05-07 | $20.00M derived: sum of 2 quarters · filed 2024-05-07 | $24.05M derived: sum of 3 quarters · filed 2024-05-07 | $24.05M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $4.05M derived: sum of 2 quarters · filed 2024-03-12 | $4.05M derived: sum of 3 quarters · filed 2024-03-12 | $4.05M 10-K · filed 2024-03-12 |
| 2022-09-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.05M derived: sum of 2 quarters · filed 2023-11-07 | $4.05M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |